Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Structural Modeling Insights into Human VKORC1 Phenotypes.

Authors: Czogalla, KJ  Watzka, M  Oldenburg, J 
Citation: Czogalla KJ, etal., Nutrients. 2015 Aug 14;7(8):6837-51. doi: 10.3390/nu7085313.
Pubmed: (View Article at PubMed) PMID:26287237
DOI: Full-text: DOI:10.3390/nu7085313

Vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1) catalyses the reduction of vitamin K and its 2,3-epoxide essential to sustain gamma-carboxylation of vitamin K-dependent proteins. Two different phenotypes are associated with mutations in human VKORC1. The majority of mutations cause resistance to 4-hydroxycoumarin- and indandione-based vitamin K antagonists (VKA) used in the prevention and therapy of thromboembolism. Patients with these mutations require greater doses of VKA for stable anticoagulation than patients without mutations. The second phenotype, a very rare autosomal-recessive bleeding disorder caused by combined deficiency of vitamin K dependent clotting factors type 2 (VKCFD2) arises from a homozygous Arg98Trp mutation. The bleeding phenotype can be corrected by vitamin K administration. Here, we summarize published experimental data and in silico modeling results in order to rationalize the mechanisms of VKA resistance and VKCFD2.


Molecular Pathway Annotations
Objects Annotated

Additional Information

RGD Object Information
RGD ID: 11354881
Created: 2016-07-28
Species: All species
Last Modified: 2016-07-28
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.